MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
← catalyst calendarNCT05464784 · readout in 133 d
Sponsored by MediciNova (industry) · MNOV — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
40estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-22 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-07-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diabetes Mellitus, Type 2
- Hypertriglyceridemia
- Non-Alcoholic Fatty Liver Disease
Interventions
- Drug: MN-001
- Drug: MN-001 placebo
Primary outcomes
what the primary-completion date above is the date OFMean change in controlled attenuation parameter (CAP) score by sound-based elastography at Week 24
measured Week 24
Mean change from baseline in fasting serum triglyceride levels at Week 24
measured Week 24
Permalink · MNOV's whole pipeline · Catalyst calendar · Every registered study · What changed